SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 4366.
  • 2
    Jemal A,Ward E,Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007; 9: R28.
  • 3
    DeVita VH,S. Rosenberg, SA. Principles and practice of oncology, 7th Bk&Cdr edn. Philadelphia: Lippincott Williams & Wilkins, 2005.
  • 4
    Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001; 27: 13742.
  • 5
    Carter CL,Allen C,Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 1817.
  • 6
    Elledge RM,McGuire WL,Osborne CK. Prognostic factors in breast cancer. Semin Oncol 1992; 19: 24453.
  • 7
    Clarke M,Collins R,Darby S,Davies C,Elphinstone P,Evans E,Godwin J,Gray R,Hicks C,James S,MacKinnon E,McGale P, et al.Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087106.
  • 8
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687717.
  • 9
    Cole BF,Gelber RD,Gelber S,Coates AS,Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001; 358: 27786.
  • 10
    Kauffman EC,Robinson VL,Stadler WM,Sokoloff MH,Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 2003; 169: 112233.
  • 11
    Steeg PS,Bevilacqua G,Kopper L,Thorgeirsson UP,Talmadge JE,Liotta LA,Sobel ME. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 2004.
  • 12
    Welch DR,Steeg PS,Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2000; 2: 40816.
  • 13
    Yoshida BA,Sokoloff MM,Welch DR,Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 2000; 92: 171730.
  • 14
    Hunter KW,Broman KW,Voyer TL,Lukes L,Cozma D,Debies MT,Rouse J,Welch DR. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 2001; 61: 886672.
  • 15
    Samant RS,Debies MT,Shevde LA,Verderame MF,Welch DR. Identification and characterization of the murine ortholog (brms1) of breast-cancer metastasis suppressor 1 (BRMS1). Int J Cancer 2002; 97: 1520.
  • 16
    Seraj MJ,Samant RS,Verderame MF,Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor. BRMS1, encoded at chromosome 11q13. Cancer Res 2000; 60: 27649.
  • 17
    Shevde LA,Samant RS,Goldberg SF,Sikaneta T,Alessandrini A,Donahue HJ,Mauger DT,Welch DR. Suppression of human melanoma metastasis by the metastasis suppressor gene. BRMS1. Exp Cell Res 2002; 273: 22939.
  • 18
    Meehan WJ,Welch DR. Breast cancer metastasis suppressor 1: update. Clin Exp Metastasis 2003; 20: 4550.
  • 19
    Cicek M,Fukuyama R,Welch DR,Sizemore N,Casey G. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 2005; 65: 358695.
  • 20
    Samant RS,Clark DW,Fillmore RA,Cicek M,Metge BJ,Chandramouli KH,Chambers AF,Casey G,Welch DR,Shevde LA. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007; 6: 6.
  • 21
    DeWald DB,Torabinejad J,Samant RS,Johnston D,Erin N,Shope JC,Xie Y,Welch DR. Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells. Cancer Res 2005; 65: 7137.
  • 22
    Saunders MM,Seraj MJ,Li Z,Zhou Z,Winter CR,Welch DR,Donahue HJ. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001; 61: 17657.
  • 23
    Meehan WJ,Samant RS,Hopper JE,Carrozza MJ,Shevde LA,Workman JL,Eckert KA,Verderame MF,Welch DR. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 2004; 279: 15629.
  • 24
    Coppola D,Szabo M,Boulware D,Muraca P,Alsarraj M,Chambers AF,Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 18490.
  • 25
    Rittling SR,Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 187781.
  • 26
    Singhal H,Bautista DS,Tonkin KS,O'Malley FP,Tuck AB,Chambers AF,Harris JF. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 60511.
  • 27
    Bramwell VH,Doig GS,Tuck AB,Wilson SM,Tonkin KS,Tomiak A,Perera F,Vandenberg TA,Chambers AF. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006; 12: 333743.
  • 28
    Tuck AB,Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6: 41929.
  • 29
    Tuck AB,O'Malley FP,Singhal H,Harris JF,Tonkin KS,Kerkvliet N,Saad Z,Doig GS,Chambers AF. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79: 5028.
  • 30
    Cook AC,Tuck AB,McCarthy S,Turner JG,Irby RB,Bloom GC,Yeatman TJ,Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 2005; 43: 22536.
  • 31
    Adwan H,Bauerle T,Najajreh Y,Elazer V,Golomb G,Berger MR. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 2004; 24: 123544.
  • 32
    Allan AL,George R,Vantyghem SA,Lee MW,Hodgson NC,Engel CJ,Holliday RL,Girvan DP,Scott LA,Postenka CO,Al-Katib W,Stitt LW, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 2006; 169: 23346.
  • 33
    Furger KA,Allan AL,Wilson SM,Hota C,Vantyghem SA,Postenka CO,Al-Katib W,Chambers AF,Tuck AB. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 2003; 1: 8109.
  • 34
    Mi Z,Guo H,Wai PY,Gao C,Wei J,Kuo PC. Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem 2004; 279: 4665967.
  • 35
    Price JE,Polyzos A,Zhang RD,Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 71721.
  • 36
    Rae JM,Creighton CJ,Meck JM,Haddad BR,Johnson MD. MDA-MB-435 cells are derived from M14 Melanoma cells–a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007; 104: 139.
  • 37
    Rae JM,Ramus SJ,Waltham M,Armes JE,Campbell IG,Clarke R,Barndt RJ,Johnson MD,Thompson EW. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 2004; 21: 54352.
  • 38
    Young MF,Kerr JM,Termine JD,Wewer UM,Wang MG,McBride OW,Fisher LW. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990; 7: 491502.
  • 39
    Tuck AB,Hota C,Chambers AF. Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001; 70: 197204.
  • 40
    Cook AC,Chambers AF,Turley EA,Tuck AB. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem 2006; 281: 243819.
  • 41
    Liu L,Cash TP,Jones RG,Keith B,Thompson CB,Simon MC. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006; 21: 52131.
  • 42
    Tucci M,Nygard K,Tanswell BV,Farber HW,Hill DJ,Han VK. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. JEndocrinol 1998; 157: 1324.
  • 43
    Vantyghem SA,Allan AL,Postenka CO,Al-Katib W,Keeney M,Tuck AB,Chambers AF. A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis 2005; 22: 35161.
  • 44
    Hicks DG,Yoder BJ,Short S,Tarr S,Prescott N,Crowe JP,Dawson AE,Budd GT,Sizemore S,Cicek M,Choueiri TK,Tubbs RR, et al. Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res 2006; 12: 67028.
  • 45
    Cameron MD,Schmidt EE,Kerkvliet N,Nadkarni KV,Morris VL,Groom AC,Chambers AF,MacDonald IC. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000; 60: 25416.
  • 46
    Khan SA,Lopez-Chua CA,Zhang J,Fisher LW,Sorensen ES,Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 2002; 85: 72836.
  • 47
    Graessmann M,Berg B,Fuchs B,Klein A,Graessmann A. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 2007; 26: 284050.
  • 48
    Minn AJ,Kang Y,Serganova I,Gupta GP,Giri DD,Doubrovin M,Ponomarev V,Gerald WL,Blasberg R,Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005; 115: 4455.
  • 49
    Denhardt DT,Noda M,O'Regan AW,Pavlin D,Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001; 107: 105561.
  • 50
    Kon S,Yokosaki Y,Maeda M,Segawa T,Horikoshi Y,Tsukagoshi H,Rashid MM,Morimoto J,Inobe M,Shijubo N,Chambers AF,Uede T. Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem 2002; 84: 42032.
  • 51
    Zhang Z,Yamashita H,Toyama T,Yamamoto Y,Kawasoe T,Iwase H. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res 2006; 12: 64104.
  • 52
    Kelly LM,Buggy Y,Hill A,O'Donovan N,Duggan C,McDermott EW,O'Higgins NJ,Young L,Duffy MJ. Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes. Tumour Biol 2005; 26: 2136.
  • 53
    Foster RS,Jr. The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am 1996; 5: 79104.
  • 54
    Yeatman TJ,Cox CE. The significance of breast cancer lymph node micrometastases. Surg Oncol Clin N Am 1999; 8: 48196,ix.
  • 55
    Palmieri D,Halverson DO,Ouatas T,Horak CE,Salerno M,Johnson J,Figg WD,Hollingshead M,Hursting S,Berrigan D,Steinberg SM,Merino MJ, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 2005; 97: 63242.